Breast CancerNCT05838001
Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy
A study testing Wire-guided localization and marker clip localization and marker clip localization in people with Breast Cancer and Breast-conserving Surgery, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Breast-conserving Surgery
- What is being tested?
- Wire-guided localization and marker clip localization and marker clip localization
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteChina
- Study dates
- 16 Feb 2023to 1 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- female patients, age≥18 year
- A score of ≥ 2 on the Eastern Cooperative Oncology Group scale
- Patients pathologically diagnosed with breast cancer by core-needle biopsy, received neoadjuvant treatment and the lesion becomes non-palpable before enrollment.
- Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery
Who cannot join
- Inflammatory breast cancer or Paget's disease
- Breast deformities and other conditions that impact breast conservation success rate
- Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded.
- Pregnancy or lactation
- Patients with hook-wire, radioactive 125I seed or other localization techniques in the breast cancer lesions before enrollment
- Patients with stage IV diseases or unresectable lesions in either breast
Show all 10Show fewer
- Patients combined with other diseases that may affect survival
- Patients with multicentric breast cancer lesions or lesions > 5 cm in diameter on imaging examinations
- Patients who have previously undergone radical mastectomy for ipsilateral breast cancer or chest wall radiotherapy
- Patients with history of ipsilateral breast cancer radical mastectomy or chest wall radiotherapy
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Sun Yat-sen University Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, 510120
Chang Gong, doctor, 02034070499, changgong282@163.com
About this study
Official title: Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neo-adjuvant Therapy : a Prospective Randomized Control Trial.
The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer.
- Conditions
- Breast Cancer, Breast-conserving Surgery
- Being tested
- Wire-guided localization and marker clip localization, marker clip localization
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wire-guided localization and marker clip localizationProcedure or surgery
Positioning guide wire and marker clip in the center of the breast lesion
marker clip localizationProcedure or surgery
Positioning marker clip in the center of the breast lesion
| Study group | Role | What they receive |
|---|---|---|
| patients after neoadjuvant therapy-combined localization | Experimental | Not described Receives: Procedure: Wire-guided localization and marker clip localization |
| patients after neoadjuvant therapy-single localization | Active comparator | Not described Receives: Procedure: marker clip localization |
What is being measured
The primary outcome is the main question the study is designed to answer.
Marginal positive rate
Proportion of patients with positive margin (intraoperative freezing and postoperative pathological margin tissue showing cancer)
Measured: up to 3 months
Secondary outcomes (3)
Re-operation rate.
the proportion of patients which have a positive margin and requires a re-operation
Measured: up to 3 months
The proportion of breast-conserving surgery.
It refers to the proportion of patients who have successfully undergone breast-conserving surgery.
Measured: up to 3 months
IDFS
Time from surgery to the first occurrence of local, distant disease recurrence, or death.
Measured: 2 years, 3 years, and 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2023
- Study start16 Feb 2023
- Primary completion1 Dec 2025 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chang Gong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05838001
- Sponsor's protocol ID
- SYSKY-2023-129-02
- Status last verified
- Jul 2024
- First submitted
- 2 Apr 2023
- Last updated
- 3 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neo-adjuvant Therapy : a Prospective Randomized Control Trial.
- ClinicalTrials.gov ID
- NCT05838001
- Acronym / sponsor ID
- SYSKY-2023-129-02
- Conditions
- Breast Cancer, Breast-conserving Surgery
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 16 Feb 2023 (actual)
- Primary completion
- 1 Dec 2025 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 1 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients after neoadjuvant therapy-combined localization | Experimental | Procedure: Wire-guided localization and marker clip localization |
| patients after neoadjuvant therapy-single localization | Active comparator | Procedure: marker clip localization |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- female patients, age≥18 year
- A score of ≥ 2 on the Eastern Cooperative Oncology Group scale
- Patients pathologically diagnosed with breast cancer by core-needle biopsy, received neoadjuvant treatment and the lesion becomes non-palpable before enrollment.
- Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery
Key exclusion criteria (10 listed)
- Inflammatory breast cancer or Paget's disease
- Breast deformities and other conditions that impact breast conservation success rate
- Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded.
- Pregnancy or lactation
- Patients with hook-wire, radioactive 125I seed or other localization techniques in the breast cancer lesions before enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wire-guided localization and marker clip localizationPositioning guide wire and marker clip in the center of the breast lesion | Procedure or surgery | patients after neoadjuvant therapy-combined localization |
| marker clip localizationPositioning marker clip in the center of the breast lesion | Procedure or surgery | patients after neoadjuvant therapy-single localization |
Primary outcome
Marginal positive rate
Time frame: up to 3 months
Proportion of patients with positive margin (intraoperative freezing and postoperative pathological margin tissue showing cancer)
3 secondary outcomes
Re-operation rate.
Time frame: up to 3 months
The proportion of breast-conserving surgery.
Time frame: up to 3 months
IDFS
Time frame: 2 years, 3 years, and 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2024.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Wire-guided localization and marker clip localization and marker clip localization in people with Breast Cancer and Breast-conserving Surgery, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chang Gong, doctor (02034070499, changgong282@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Marginal positive rate (time frame: up to 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2024.